2020 Full year and fourth quarter
We will announce our full year and fourth quarter 2020 results at 12:00 GMT, 07:00 EST on Wednesday 3 February 2021.
Following the announcement there will be a webcast hosted by Emma Walmsley, CEO, Iain Mackay, CFO and Dr Hal Barron, Chief Scientific Officer and President of R&D at 14:00 GMT, 09:00 EST.
2017 Third quarter
We announced our third quarter 2017 results on Wednesday 25 October.
2017 Second quarter and investor event
We announced our second quarter 2017 results on 26 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our strategic priorities and financial outlook.
- Q2 2017 results announcement PDF - 1.9MB
- Q2 2017 results video transcript PDF - 177.6KB
- Q2 2017 US dollar translation PDF - 121.7KB
- Q2 2017 results infographic PDF - 862.6KB
- Q2 2017 pre announcement aide memoire PDF - 795.1KB
- Emma Walmsley slides: Key priorities PDF - 864.3KB
- Simon Dingemans slides: Q2 and financial outlook PDF - 509.3KB
- Investor event full transcript PDF - 173.6KB
2017 First quarter
Watch Simon Dingemans, CFO, GSK, discuss our first quarter results 2017.
2016 Full year and fourth quarter
Watch Sir Andrew Witty, CEO, and Simon Dingemans, CFO discuss our full year 2016 results. Watch Patrick Vallance, President, Pharmaceuticals R&D, give an update on R&D.
- Q4 2016 results announcement PDF - 1.8MB
- Q4 2016 analyst slide presentation PDF - 606.8KB
- Q4 2016 results transcript PDF - 76.6KB
- Q4 2016 results highlights infographic PDF - 895.6KB
- Q4 2016 US dollar translation PDF - 128.4KB
- Q4 2016 actual growth schedules PDF - 132.2KB
- Q4 2016 pre announcement aide memoire PDF - 1,020.8KB
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers